02:00 Mon 02 Dec 2019
Adv Medical Soln Grp - Acquisition of Biomatlante SA
("AMS", the "Company" or the "Group")
Acquisition of
-
- Biomatlante provides access to an additional
- Provides a significant patent estate and a development pipeline of next-generation products
Acquisition rationale and benefits
The acquisition will strengthen AMS's product portfolio, R&D pipeline, and market access. It provides the Group with a range of revenue-generating surgical products and an R&D pipeline of complementary biosurgical technologies and offers significant growth potential in additional surgical markets estimated to be worth
Biomatlante's biosurgical products, which are sold mainly in
The R&D pipeline and platform technologies which AMS acquired will broaden the Group's biosurgical technology offering while also offering multiple synergies across the sales, marketing, regulatory, operational divisions and R&D.
Terms of the transaction
The Acquisition is for an initial consideration of
Overview of Biomatlante
Biomatlante has a patent-protected technology platform with a wide range of biomaterial products used in orthopaedic, spinal, dental and sports surgery and a development pipeline of next-generation products. The company's commercialised products, which are approved for sale in over 50 countries worldwide, include synthetic bone substitutes, collagen membranes and bioabsorbable screws. In addition to the marketed products.
For its financial year ended
Biomatlante employs 36 full time staff and operates two fully-equipped modern facilities close to Nantes in
Biomatlante is ISO 13485 and MDSAP accredited with extensive clinical evidence and is well prepared for the new European Medical Device Regulation.
Commenting on the acquisition,
Commenting this acquisition, Chantal GOBIN-DACULSI, Co-founder and President of Biomatlante said: "This is an important stragecic step for Biomatlante and we are excited to become part of the AMS group. AMS is a high quality global Company with the scale, expertise and track record of realising the value of scienitific innovation and rapidly growing the sales of marketed products. Our product portfolios, product pipelines and geographic footprints are highly complementary, and, as part of the AMS family, the know-how of our team can be fully realised, allowing our pipeline of synthetic bone substitutes to be commercialised on a global scale."
- End -
For further information, please visit www.admedsol.com or contact:
|
Tel: +44 (0) 1606 545508 |
|
|
|
|
|
Tel: +44 (0) 20 3709 5700 |
|
|
|
|
|
Tel: +44 (0) 20 7597 5970 |
|
|
About
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand®, RESORBA®, and LiquiBandFix8®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group acquired Sealantis, an Israeli-based medical device company with a patent-protected internal sealant technology platform.
AMS's products, manufactured in the
About Biomatlante
A pioneer in biologics solutions, Biomatlante develops, manufactures and commercialises synthetic bone graft technologies.
Biomatlante specializes in producing synthetic biomaterials for bone regeneration and is a world leader in bone graft technologies, selling its products in over 50 countries. Biomatlante's products are routinely used in orthopaedics and trauma surgery, in spine, ENT, maxillofacial and dental surgery.
Biomatlante collaborates closely with universities and research centers across the world:
Amongst others, it collaborates with CNRS (
MBCP® Technology is a biphasic calcium phosphate synthetic bone graft substitute platform with a unique micro and macroporous structure that most closely resembles to the architecture of natural human bone. MBCP® Technology products are available in different shapes (granules, blocks and anatomical shapes), injectable/moldable putty, resorbable osteosynthesis (based on specific composite material combining MBCP® granules and polymers), and MBCP® + smart scaffold for bone tissue engineering to be associated with total bone marrow or expended mesenchymal stem cells. Proven Osteogenic and osteoinductive properties are related to the Biomatlante bioactive ceramic. EZ-Cure® collagenic membrane, complementary product to the bone graft line, is proposed to dental surgeon for a full surgical solution in maxillofacial surgery.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE